The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic and predictive value of circulating tumour DNA (ctDNA) by amplicon-based next generation sequencing (NGS) of advanced pancreatic cancer (APC) in a phase I trial of oxaliplatin capecitabine and irinotecan (OXIRI) triplet chemotherapy.
 
Amanda Oon Lim Seet
No Relationships to Disclose
 
Su Pin Choo
No Relationships to Disclose
 
David Wai-Meng Tai
No Relationships to Disclose
 
Justina Yick Ching Lam
No Relationships to Disclose
 
Tira Jing Ying Tan
Consulting or Advisory Role - Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer
Research Funding - Bayer; Bayer; Bayer; Bayer; Novartis; Novartis; Novartis; Novartis
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Eisai; Eisai; Eisai; Eisai; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Pfizer; Pfizer; Pfizer; Pfizer
 
Daniel Shao-Weng Tan
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Roche; Roche; Roche; Roche; Takeda; Takeda; Takeda; Takeda
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Loxo; Loxo; Loxo; Loxo; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Roche; Roche; Roche; Roche
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Pfizer; Pfizer; Pfizer; Pfizer; Roche; Roche; Roche; Roche
 
Aaron C. Tan
Travel, Accommodations, Expenses - ASLAN Pharmaceuticals; ASLAN Pharmaceuticals; ASLAN Pharmaceuticals; ASLAN Pharmaceuticals; Pfizer; Pfizer; Pfizer; Pfizer
 
Yvonne Chang
No Relationships to Disclose
 
Balram Chowbay
No Relationships to Disclose
 
Matthew C.H. Ng
Honoraria - ASLAN Pharmaceuticals; ASLAN Pharmaceuticals; ASLAN Pharmaceuticals; ASLAN Pharmaceuticals; Lilly; Lilly; Lilly; Lilly; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology
Speakers' Bureau - Lilly; Lilly; Lilly; Lilly
Research Funding - ASLAN Pharmaceuticals (Inst); ASLAN Pharmaceuticals (Inst); ASLAN Pharmaceuticals (Inst); ASLAN Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical